← Back
Data updated: Mar 29, 2026
HANGZHOU BINJIANG
Cardiovascular
Generics
HANGZHOU BINJIANG is a generic drug manufacturer focused on Cardiovascular.
2009
Since
4
Drugs
-
Trials
22
Approved (2yr)
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
ALENDRONATE SODIUM 2026-02-03
Labeling
ALENDRONATE SODIUM 2026-02-03
Labeling
ALENDRONATE SODIUM 2026-01-28
Labeling
ALENDRONATE SODIUM 2026-01-28
Labeling
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE 2025-10-10
Labeling
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE 2025-09-30
Labeling
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE 2025-09-30
Labeling
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE 2025-09-26
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 100%
1 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Discontinued (1)
Company Info
- First Approval
- 2009-09-24
- Latest
- 2025-08-20
- Applications
- 4